AGL 39.50 Increased By ▲ 1.48 (3.89%)
AIRLINK 207.20 Increased By ▲ 9.84 (4.99%)
BOP 9.65 Increased By ▲ 0.11 (1.15%)
CNERGY 6.04 Increased By ▲ 0.13 (2.2%)
DCL 8.90 Increased By ▲ 0.08 (0.91%)
DFML 36.70 Increased By ▲ 0.96 (2.69%)
DGKC 98.37 Increased By ▲ 1.51 (1.56%)
FCCL 35.40 Increased By ▲ 0.15 (0.43%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.42 Increased By ▲ 0.25 (1.9%)
HUBC 129.50 Increased By ▲ 1.95 (1.53%)
HUMNL 13.70 Increased By ▲ 0.20 (1.48%)
KEL 5.43 Increased By ▲ 0.11 (2.07%)
KOSM 7.10 Increased By ▲ 0.10 (1.43%)
MLCF 45.00 Increased By ▲ 0.30 (0.67%)
NBP 62.40 Increased By ▲ 0.98 (1.6%)
OGDC 217.25 Increased By ▲ 2.58 (1.2%)
PAEL 41.06 Increased By ▲ 2.27 (5.85%)
PIBTL 8.32 Increased By ▲ 0.07 (0.85%)
PPL 196.16 Increased By ▲ 3.08 (1.6%)
PRL 39.10 Increased By ▲ 0.44 (1.14%)
PTC 26.75 Increased By ▲ 0.95 (3.68%)
SEARL 105.90 Increased By ▲ 2.30 (2.22%)
TELE 8.37 Increased By ▲ 0.07 (0.84%)
TOMCL 35.50 Increased By ▲ 0.50 (1.43%)
TPLP 13.53 Increased By ▲ 0.23 (1.73%)
TREET 22.58 Increased By ▲ 0.42 (1.9%)
TRG 60.28 Increased By ▲ 4.69 (8.44%)
UNITY 33.25 Increased By ▲ 0.28 (0.85%)
WTL 1.71 Increased By ▲ 0.11 (6.88%)
BR100 11,889 Increased By 162.9 (1.39%)
BR30 36,977 Increased By 600.2 (1.65%)
KSE100 111,462 Increased By 1948.5 (1.78%)
KSE30 35,172 Increased By 658.8 (1.91%)

AstraZeneca on Friday beat first-quarter sales and profit expectations and stood by its forecasts for 2022 as newer therapies for kidney disease and rare conditions offset an expected decline in COVID-19 vaccine sales.

It expects sales of its antibody-based COVID-19 treatment, Evusheld, to grow this year, but that will be more than outweighed by a decline in sales of its vaccine developed with Oxford University amid growing competition, concerns about its shelf life and vaccine hesitancy.

The vaccine recorded $1.15 billion in sales in the quarter, the majority of which came from initial contracts, while the antibody treatment brought in $469 million.

The two-dose shot was AstraZeneca’s second best-selling product in 2021 with sales of $3.9 billion.

AstraZeneca’s total revenue jumped 60% to $11.39 billion for the three months ended March 31 on a constant-currency basis.

Core earnings of $1.89 per share were helped by strong sales of products such as Farxiga for diabetes and kidney and the vaccine.

Analysts on average were expecting profit of $1.70 per share on revenue of $10.85 billion, Refinitiv IBES data showed.

However, sales of its top three oncology drugs - Tagrisso, Imfinzi and Lynparza - missed consensus expectations.

Even though COVID-19 levels are beginning to wane, access to cancer diagnoses and treatment has still not rebounded to pre-pandemic levels.

Comments

Comments are closed.